File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma

TitleOverexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma
Authors
KeywordssiRNA
Transferrin receptor
CD71
Esophageal squamous cell carcinoma
Issue Date2014
PublisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htm
Citation
Oncology Reports, 2014, v. 31 n. 3, p. 1296-1304 How to Cite?
AbstractEsophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in endemic Asian regions. In the present study, we investigated the clinical implication and role of transferrin receptor CD71 in ESCC. CD71 has a physiological role in cellular iron intake and is implicated in the carcinogenesis of various types of tumors. In our cohort, more than a 2-fold upregulation of the CD71 transcript was detected in 61.5% of patients using quantitative polymerase chain reaction. Immunohistochemical analysis also showed strong membranous and cytoplasmic localization of CD71 in paraffin-embedded tumors. Staining parallel tumor sections with the proliferative marker Ki-67 revealed that the pattern of Ki-67 staining was associated with CD71 expression. Analysis of clinicopathological data indicated that CD71 overexpression can be used as an indicator for advanced T4 stage (P=0.0307). These data suggested a strong link between CD71 and ESCC. Subsequent in vitro assays using short interfering RNA (siRNA) to suppress CD71 expression confirmed the tumorigenic properties of CD71 in ESCC; cell growth inhibition and cell cycle arrest at S phase were observed in CD71-suppressed cells. The underlying mechanism involved activation of the MEK/ERK pathway. In summary, the present study provides evidence showing the tumorigenic properties of CD71 in ESCC with clinical correlations and suggests targeting CD71 as a strategy for the treatment of ESCC.
Persistent Identifierhttp://hdl.handle.net/10722/195932
ISSN
2015 Impact Factor: 2.486
2015 SCImago Journal Rankings: 0.968
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, KTen_US
dc.contributor.authorChoi, MYen_US
dc.contributor.authorLai, KYen_US
dc.contributor.authorTan, Wen_US
dc.contributor.authorTung, LNen_US
dc.contributor.authorLam, DHYen_US
dc.contributor.authorTong, DKHen_US
dc.contributor.authorLee, NPYen_US
dc.contributor.authorLaw, SYKen_US
dc.date.accessioned2014-03-21T02:22:38Z-
dc.date.available2014-03-21T02:22:38Z-
dc.date.issued2014en_US
dc.identifier.citationOncology Reports, 2014, v. 31 n. 3, p. 1296-1304en_US
dc.identifier.issn1021-335X-
dc.identifier.urihttp://hdl.handle.net/10722/195932-
dc.description.abstractEsophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in endemic Asian regions. In the present study, we investigated the clinical implication and role of transferrin receptor CD71 in ESCC. CD71 has a physiological role in cellular iron intake and is implicated in the carcinogenesis of various types of tumors. In our cohort, more than a 2-fold upregulation of the CD71 transcript was detected in 61.5% of patients using quantitative polymerase chain reaction. Immunohistochemical analysis also showed strong membranous and cytoplasmic localization of CD71 in paraffin-embedded tumors. Staining parallel tumor sections with the proliferative marker Ki-67 revealed that the pattern of Ki-67 staining was associated with CD71 expression. Analysis of clinicopathological data indicated that CD71 overexpression can be used as an indicator for advanced T4 stage (P=0.0307). These data suggested a strong link between CD71 and ESCC. Subsequent in vitro assays using short interfering RNA (siRNA) to suppress CD71 expression confirmed the tumorigenic properties of CD71 in ESCC; cell growth inhibition and cell cycle arrest at S phase were observed in CD71-suppressed cells. The underlying mechanism involved activation of the MEK/ERK pathway. In summary, the present study provides evidence showing the tumorigenic properties of CD71 in ESCC with clinical correlations and suggests targeting CD71 as a strategy for the treatment of ESCC.-
dc.languageengen_US
dc.publisherDemetrios A Spandidos Ed & Pub. The Journal's web site is located at http://147.52.72.117/OR/or.htm-
dc.relation.ispartofOncology Reportsen_US
dc.subjectsiRNA-
dc.subjectTransferrin receptor-
dc.subjectCD71-
dc.subjectEsophageal squamous cell carcinoma-
dc.titleOverexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailChan, KT: ktchan66@hku.hken_US
dc.identifier.emailChoi, MY: choimyd@hku.hken_US
dc.identifier.emailTan, W: tanw@hku.hken_US
dc.identifier.emailTung, LN: lainar@hku.hken_US
dc.identifier.emailLam, DHY: dodolhy@hku.hken_US
dc.identifier.emailTong, DKH: esodtong@hku.hken_US
dc.identifier.emailLee, NPY: nikkilee@hku.hken_US
dc.identifier.emailLaw, SYK: slaw@hku.hken_US
dc.identifier.authorityLee, NPY=rp00263en_US
dc.identifier.authorityLaw, SYK=rp00437en_US
dc.identifier.doi10.3892/or.2014.2981-
dc.identifier.pmid24435655-
dc.identifier.scopuseid_2-s2.0-84896706759-
dc.identifier.hkuros228318en_US
dc.identifier.volume31en_US
dc.identifier.issue3en_US
dc.identifier.spage1296en_US
dc.identifier.epage1304en_US
dc.identifier.isiWOS:000332693700036-
dc.publisher.placeGreece-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats